ERBB2 and non-small cell lung carcinoma: HER2 overexpression has been described in a variety of tumours including, but not limited to, bladder, breast, cervix, colorectal, endometrium, oesophagus, gastric, head and neck, liver, melanoma, lung (NSCLC), osteosarcoma, ovary, prostate and salivary duct [8].